MCID: SVR002
MIFTS: 34

Severe Nonproliferative Diabetic Retinopathy

Categories: Eye diseases

Aliases & Classifications for Severe Nonproliferative Diabetic Retinopathy

MalaCards integrated aliases for Severe Nonproliferative Diabetic Retinopathy:

Name: Severe Nonproliferative Diabetic Retinopathy 12 15 73
High Risk Non Proliferative Diabetic Retinopathy 12
Severe Npdr 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8946
ICD9CM 35 362.06
UMLS 73 C0730278

Summaries for Severe Nonproliferative Diabetic Retinopathy

MalaCards based summary : Severe Nonproliferative Diabetic Retinopathy, also known as high risk non proliferative diabetic retinopathy, is related to microvascular complications of diabetes 5 and acroosteolysis. An important gene associated with Severe Nonproliferative Diabetic Retinopathy is STK38L (Serine/Threonine Kinase 38 Like), and among its related pathways/superpathways are HIF-1 signaling pathway and Differentiation Pathway. The drugs Bevacizumab and Angiogenesis Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include eye, liver and endothelial, and related phenotypes are nervous system and vision/eye

Related Diseases for Severe Nonproliferative Diabetic Retinopathy

Diseases related to Severe Nonproliferative Diabetic Retinopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 40)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 5 29.8 ALB INS VEGFA
2 acroosteolysis 10.2 ALB VEGFA
3 hypertensive nephropathy 10.2 ALB VEGFA
4 gastric lymphoma 10.2 ALB VEGFA
5 hydrops, lactic acidosis, and sideroblastic anemia 10.1 ALB VEGFA
6 hepatopulmonary syndrome 10.1 ALB VEGFA
7 intermittent claudication 10.1 ALB VEGFA
8 ovarian hyperstimulation syndrome 10.1 ALB VEGFA
9 severe pre-eclampsia 10.1 ALB VEGFA
10 brain edema 10.1 ALB VEGFA
11 hypoglycemic coma 10.1 INS VEGFA
12 burns 10.1 ALB INS
13 portal hypertension 10.0 ALB VEGFA
14 fetal erythroblastosis 10.0 ALB INS
15 noma 10.0 ALB INS
16 autonomic nervous system disease 10.0 ALB INS
17 prediabetes syndrome 10.0 ALB INS
18 rubeosis iridis 10.0 INS VEGFA
19 choroiditis 10.0
20 microvascular complications of diabetes 3 10.0 ALB INS
21 peripheral vascular disease 10.0 ALB VEGFA
22 female reproductive system disease 10.0 INS VEGFA
23 autonomic neuropathy 9.9 ALB INS
24 sleep apnea 9.9 INS VEGFA
25 diabetic neuropathy 9.9 INS VEGFA
26 uremia 9.9 ALB INS
27 glucose metabolism disease 9.8 ALB INS
28 gastrointestinal system cancer 9.8 ALB VEGFA
29 urinary system disease 9.8 ALB INS
30 acquired metabolic disease 9.8 ALB INS
31 autosomal dominant polycystic kidney disease 9.6 ALB VEGFA
32 background diabetic retinopathy 9.5 ALB INS VEGFA
33 retinal vascular disease 9.5 ALB INS VEGFA
34 arteries, anomalies of 9.5 ALB INS VEGFA
35 nervous system disease 9.5 ALB INS VEGFA
36 vascular disease 9.4 ALB INS VEGFA
37 hyperglycemia 9.2 ALB INS
38 ewing sarcoma 9.2 ALB INS VEGFA
39 myocardial infarction 9.0 ALB INS VEGFA
40 diabetes mellitus 9.0 ALB INS VEGFA

Graphical network of the top 20 diseases related to Severe Nonproliferative Diabetic Retinopathy:



Diseases related to Severe Nonproliferative Diabetic Retinopathy

Symptoms & Phenotypes for Severe Nonproliferative Diabetic Retinopathy

MGI Mouse Phenotypes related to Severe Nonproliferative Diabetic Retinopathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.35 INS OPN4 SEMA3E STK38L VEGFA
2 vision/eye MP:0005391 8.92 INS OPN4 SEMA3E VEGFA

Drugs & Therapeutics for Severe Nonproliferative Diabetic Retinopathy

Drugs for Severe Nonproliferative Diabetic Retinopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 31)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3 216974-75-3
2 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3
3 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3
4
Ranibizumab Approved Phase 3 347396-82-1 459903
5
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
6
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
7 triamcinolone acetonide Phase 3
8 glucocorticoids Phase 3
9 Hormone Antagonists Phase 3
10 Triamcinolone diacetate Phase 3
11 Triamcinolone hexacetonide Phase 3
12 Hormones Phase 3
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
14 Pharmaceutical Solutions Phase 3
15 Immunosuppressive Agents Phase 3
16 Anti-Inflammatory Agents Phase 3
17 Mitogens Phase 3
18 Endothelial Growth Factors Phase 3
19 Gastrointestinal Agents Phase 3
20 Antineoplastic Agents, Hormonal Phase 3
21
Fibrinolysin Investigational Phase 2 9004-09-5
22 Fibrinolytic Agents Phase 2
23
Menthol Approved Not Applicable 2216-51-5 16666
24 Liver Extracts
25 Mydriatics
26 Peripheral Nervous System Agents
27 Autonomic Agents
28 Trientine Not Applicable
29 insulin Not Applicable
30 Chelating Agents Not Applicable
31 Insulin, Globin Zinc Not Applicable

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 Avastin for Post-Photocoagulation Macular Edema Completed NCT00801866 Phase 4 Bevacizumab
2 Panretinal Photocoagulation for Diabetic Retinopathy With PASCAL Laser Unknown status NCT01304225 Phase 3
3 Intravitreal Bevacizumab for Diabetic Retinopathy Completed NCT00600262 Phase 2, Phase 3 intravitreal bevacizumab
4 Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema Completed NCT00444600 Phase 3 Triamcinolone Acetonide + laser;Ranibizumab + laser;Sham injection + laser;Ranibizumab + deferred laser
5 A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE) Completed NCT00473382 Phase 3 Ranibizumab;Sham injection
6 A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE) Completed NCT00473330 Phase 3 Ranibizumab;Sham injection
7 Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) Active, not recruiting NCT02718326 Phase 3 Intravitreal aflibercept injection [IAI];Sham
8 Anti-VEGF Treatment for Prevention of PDR/DME Active, not recruiting NCT02634333 Phase 3 Prompt aflibercept;Deferred aflibercept
9 Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy Terminated NCT00248131 Phase 3 Octreotide acetate in microspheres
10 Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy Terminated NCT00248157 Phase 3 Octreotide acetate in microspheres
11 Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment Completed NCT00198471 Phase 2 Vitrase
12 A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated. Recruiting NCT03238963 Phase 2 BI 1467335;Placebo
13 Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement Recruiting NCT03531294 Phase 2 Aflibercept Injection
14 The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR) Active, not recruiting NCT03197870 Phase 2 AKB-9778;Placebo
15 A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR Active, not recruiting NCT02681809 Phase 2 ocriplasmin 0.0625mg;ocriplasmin 0.125mg;Sham injection
16 A Study of Keluo Xin Capsule Compare to Placebo in Terms of Efficacy and Safety in Patients With Diabetic Retinopathy Not yet recruiting NCT03258242 Phase 2 Keluo Xin capsule;Placebo oral capsule
17 Panretinal Photo-stimulation in Proliferative Diabetic Retinopathy Unknown status NCT02309502 Not Applicable
18 Diabetic Macular Edema and Diabetic Retinopathy Screening (TeleMed) With Automated Retinal Photography Unknown status NCT01790945
19 Study on Tear Proteins in Diabetic Retinopathy of Type 2 Diabetics Unknown status NCT00698698
20 Observational Study of DME Following Scatter Laser Photocoagulation Completed NCT00687154 Not Applicable
21 Smartphone-based Ophthalmoscopy Completed NCT02177747 Not Applicable
22 Safety and Effectiveness Study of 532nm Laser Subthreshold Panretinal Photocoagulation for Severe NPDR Recruiting NCT01759121 Not Applicable
23 Early Laser Treatment for Diabetic Eye Disease in China : A Pilot Randomized Trial Recruiting NCT02956759 Not Applicable
24 Thermal Screening for Early Diabetic Peripheral Neuropathy (DPN) Recruiting NCT03069729
25 OCT Biomarkers for Diabetic Retinopathy Recruiting NCT02330042
26 Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR) Recruiting NCT03403686
27 Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool Enrolling by invitation NCT03112005 Mydriatic Agent
28 Simple, Mobile-based Artificial Intelligence AlgoRithms in the Detection of Diabetic ReTinopathy (SMART) Study Not yet recruiting NCT03572699
29 Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy Terminated NCT01213888 Not Applicable Trientine Hydrochloride;Oral placebo capsules
30 Choroidal Blood Flow Changes During Dark/Light Transitions in Patients With Insulin-dependent Diabetes Mellitus (IDDM) Terminated NCT00718614 Not Applicable

Search NIH Clinical Center for Severe Nonproliferative Diabetic Retinopathy

Genetic Tests for Severe Nonproliferative Diabetic Retinopathy

Anatomical Context for Severe Nonproliferative Diabetic Retinopathy

MalaCards organs/tissues related to Severe Nonproliferative Diabetic Retinopathy:

41
Eye, Liver, Endothelial, Testes, Retina

Publications for Severe Nonproliferative Diabetic Retinopathy

Articles related to Severe Nonproliferative Diabetic Retinopathy:

# Title Authors Year
1
Venous beading in two or more quadrants might not be a sensitive grading criterion for severe nonproliferative diabetic retinopathy. ( 29626228 )
2018
2
EFFECTS OF PANRETINAL PHOTOCOAGULATION ON CHOROIDAL THICKNESS AND CHOROIDAL BLOOD FLOW IN PATIENTS WITH SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY. ( 26447396 )
2015
3
Intravitreal bevacizumab versus panretinal photocoagulation for treatment-naA^ve proliferative and severe nonproliferative diabetic retinopathy. ( 22405048 )
2012
4
The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. ( 15983221 )
2005
5
Influence of laser coagulation therapy on untreated fellow-eyes in severe nonproliferative diabetic retinopathy-spectrometric results. ( 9469548 )
1997
6
Different determinants of neovascularization on the optic disc and on the retina in patients with severe nonproliferative diabetic retinopathy. ( 7679270 )
1993

Variations for Severe Nonproliferative Diabetic Retinopathy

Expression for Severe Nonproliferative Diabetic Retinopathy

Search GEO for disease gene expression data for Severe Nonproliferative Diabetic Retinopathy.

Pathways for Severe Nonproliferative Diabetic Retinopathy

Pathways related to Severe Nonproliferative Diabetic Retinopathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.32 INS VEGFA
2 10.94 INS VEGFA
3 10.92 ALB INS VEGFA
4 10.8 ALB INS
5
Show member pathways
10.58 INS VEGFA

GO Terms for Severe Nonproliferative Diabetic Retinopathy

Cellular components related to Severe Nonproliferative Diabetic Retinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.26 ALB INS SEMA3E VEGFA
2 platelet alpha granule lumen GO:0031093 8.62 ALB VEGFA

Biological processes related to Severe Nonproliferative Diabetic Retinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.5 ALB INS VEGFA
2 platelet degranulation GO:0002576 9.37 ALB VEGFA
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.26 INS VEGFA
4 branching involved in blood vessel morphogenesis GO:0001569 9.16 SEMA3E VEGFA
5 positive regulation of protein autophosphorylation GO:0031954 8.96 INS VEGFA
6 positive regulation of cell migration GO:0030335 8.8 INS SEMA3E VEGFA

Sources for Severe Nonproliferative Diabetic Retinopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....